저분자 API 연속 생산 시장 규모, 점유율, 동향 분석 보고서 : 장비별, 단위 작업별, 유형별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Continuous Manufacturing For Small Molecule APIs Market Size, Share & Trends Analysis Report By Equipment (Reactors, Crystallizers, Filtration Systems), By Unit Operation, By Type, By End Use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

저분자 API 연속 생산 시장 성장과 동향:

Grand View Research, Inc.의 조사 보고서에 따르면 저분자 API 연속 생산 세계 시장 규모는 2030년까지 6억 7,152만 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 연평균 10.42% 성장할 것으로 예상됩니다.

이러한 견조한 성장은 현재 업계 동향, 기술 발전 및 규제 환경의 변화를 반영하는 몇 가지 주요 촉진요인에 기인합니다. 연속 생산 공정은 기존 배치 공정에 비해 효율성 향상, 제조 비용 절감, 제품 품질 향상 등 큰 이점을 제공합니다. 미국 식품의약국(FDA)은 의약품 제조 공정을 간소화하고 전체 의약품의 품질을 향상시킬 수 있는 잠재력을 인식하고 연속 생산 기술을 적극적으로 장려하고 있습니다. 예를 들어, FDA의 '21세기 의약품 품질' 이니셔티브는 연속 생산를 중요한 중점 분야로 선정하여 기업들이 이러한 혁신적인 접근 방식을 채택하여 제조 변수를 보다 확실하게 관리할 수 있도록 장려하고 있습니다.

최근의 기술 발전은 연속 생산 시장을 더욱 촉진하고 있습니다. 공정 분석 기술(PAT)의 혁신은 생산 공정의 실시간 모니터링을 가능하게하여 일관된 품질 및 규제 표준 준수를 보장합니다. 예를 들어, 2024년 7월 GEA는 의약품 제조의 유연성과 효율성을 높이기 위해 고안된 새로운 연속 처리 기술을 발표했으며, ACHEMA 2024에서 GEA는 호비오네(Hobione)와의 협업을 통해 ConsiGma CDC 플렉스 시스템(ConsiGma CDC Flex System)을 전시했습니다. 이 시스템은 다양한 처리량에서 연속 및 배치 공정을 모두 지원하여 생산 품질과 지속가능성을 향상시킵니다. 이러한 기술은 효율성을 높일 뿐만 아니라 신약의 시장 출시 시간을 크게 단축시켜 경쟁이 치열해지는 제약 산업에 필수적인 요소로 자리 잡고 있습니다.

연속 생산 시장의 성장에는 정부의 노력과 지원도 중요한 역할을 하고 있습니다. 여러 국가들은 경쟁력을 강화하고 공중보건 성과를 개선하기 위해 의약품 제조의 현대화 필요성을 인식하고 있습니다. 예를 들어, 미국 정부는 연속 생산 기술의 채택을 촉진하기 위한 프로그램을 도입하고 업계 내 혁신을 지원하기 위해 자금과 자원을 제공하고 있습니다. 마찬가지로, 유럽의약품청(EMA)은 유럽 제약 부문에서 이러한 기술의 도입을 촉진하는 가이드라인을 추진하고 연속 공정의 사용을 장려하고 있습니다.

저분자 API 연속 생산 시장 보고서 하이라이트

• 장비별로는 원자로가 2023년 35.2%의 높은 점유율로 시장을 장악했으며, 예측 기간 동안 11.0%의 CAGR로 가장 빠른 성장을 보일 것으로 예상됩니다.
• 장비별로는 합성 장비가 2023년 39.1%로 가장 큰 매출 비중을 차지했으며, 기술 발전, 효율성 향상, 지속가능한 관행으로의 전환에 힘입어 향후 몇 년 동안 지속적으로 확대될 것으로 전망됩니다.
• 유형별로는 제네릭 원료의약품이 2023년 10.8%의 높은 매출 점유율을 차지하며 시장을 장악했습니다.
• 최종 용도별로는 CMO/CDMO가 2023년 70.2%의 높은 매출 점유율을 차지하며 시장을 주도했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 저분자 API 연속 생산 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 견인 요인 분석
  • 시장 성장 억제요인 분석
• 저분자 API 연속 생산 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 저분자 API 연속 생산 시장 : 설비 추정·동향 분석

• 저분자 API 연속 생산 세계 시장 : 기기 대시보드
• 저분자 API 연속 생산 세계 시장 : 설비 변동 분석
• 저분자 API 연속 생산 세계 시장 : 설비별 매출
• 원자로
• 결정화기
• 여과 시스템
• 믹서
• 열교환기
• 기타(건조기 등)

제5장 저분자 API 연속 생산 시장 : 단위 조작 추정·동향 분석

• 저분자 API 연속 생산 세계 시장 : 유닛 조작 대시보드
• 저분자 API 연속 생산 세계 시장 : 유닛 조작 변동 분석
• 단위 조작별 매출
• 합성
• 분리와 정제
• 건조

제6장 저분자 API 연속 생산 시장 : 유형 추정·동향 분석

• 저분자 API 연속 생산 세계 시장 : 유형 대시보드
• 저분자 API 연속 생산 세계 시장 : 유형 변동 분석
• 유형별 매출
• 범용 API
• 혁신적인 API

제7장 저분자 API 연속 생산 시장 : 최종 용도 추정·동향 분석

• 저분자 API 연속 생산 세계 시장 : 최종 용도 대시보드
• 저분자 API 연속 생산 세계 시장 : 최종 용도 변동 분석
• 최종 용도별 매출
• CMO/CDMO
• 제약회사
• 학술연구기관

제8장 저분자 API 연속 생산 시장 : 기기, 단위 조작, 유형, 최종 용도별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018년에서 2030년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제9장 경쟁 상황

• 기업/경쟁 분류
• 벤더 상황
  • 주요 판매대리점 및 채널 파트너 리스트
  • Key company market share analysis, 2023
  • Pfizer Inc
  • GSK plc.(GlaxoSmithKline)
  • Vertex Pharmaceuticals Incorporated
  • Janssen(a subsidiary of Johnson & Johnson)
  • Abbvie Inc.
  • Sterling Pharma Solutions
  • Evonik Industries AG
  • Cambrex Corporation
  • Patheon
  • Hovione
  • Lonza
  • Phlow
  • Asymchem
  • GEA Group AG
  • Thermo Fisher Scientific
  • Corning Incorporated
  • Coperion GmbH
  • Continuus Pharmaceuticals
  • Chemtrix
  • Vapourtec Ltd
  • Ehrfeld Mikrotechnik GmbH
  • NiTech Solutions Ltd

ksm

영문 목차

영문목차

Continuous Manufacturing For Small Molecule APIs Market Growth & Trends:

The global continuous manufacturing for small molecule APIs market size is anticipated to reach USD 671.52 million by 2030, growing at a CAGR of 10.42% from 2024 to 2030, according to a report by Grand View Research, Inc. This robust expansion can be attributed to several key drivers that reflect current industry trends, advancements in technology, and changing regulatory landscapes. Continuous manufacturing processes offer significant advantages over traditional batch processing, including increased efficiency, reduced production costs, and improved product quality. The United States Food and Drug Administration (FDA) has actively promoted continuous manufacturing technologies, recognizing their potential to streamline the drug production process and enhance the overall quality of pharmaceutical products. For instance, the FDA's "Pharmaceutical Quality for the 21st Century" initiative highlights continuous manufacturing as a key focus area, encouraging companies to adopt these innovative approaches to ensure better control over production variables.

Recent technological advancements further propel the continuous manufacturing market. Innovations in process analytical technology (PAT) enable real-time monitoring of production processes, ensuring consistent quality and compliance with regulatory standards. For instance, in July 2024, GEA introduced new continuous processing technologies designed to enhance flexibility and efficiency in pharmaceutical manufacturing. At ACHEMA 2024, GEA showcased its collaboration with Hovione, emphasizing the ConsiGma CDC flex system. This system supports both continuous and batch processes with varied throughput, improving production quality and sustainability. Their partnership aims to simplify operations and make continuous manufacturing more accessible across the industry.These technologies not only increase efficiency but also significantly shorten time-to-market for new drugs, an essential factor in an increasingly competitive pharmaceutical industry.

Government initiatives and support also play a crucial role in the growth of the continuous manufacturing market. Various countries are recognizing the need for modernization in pharmaceutical manufacturing to enhance competitiveness and improve public health outcomes. For example, the U.S. government has introduced programs aimed at facilitating the adoption of continuous manufacturing technologies, providing funding and resources to support innovation within the industry. Similarly, the European Medicines Agency (EMA) has been encouraging the use of continuous processes, promoting guidelines that facilitate the implementation of these technologies within Europe's pharmaceutical sector.

Continuous Manufacturing For Small Molecule APIs Market Report Highlights:

• Based on equipment, reactors dominated the market with a substantial share of 35.2% in 2023 and are expected to grow at the fastest CAGR of 11.0% during the forecast period
• Based on unit operation, the synthesis segment held the largest revenue share of 39.1% in 2023 driven by technological advancements, efficiency gains, and a shift toward sustainable practices, positioning it for continued expansion in the coming years
• Based on type, generic APIs dominated the market, capturing a substantial revenue share of 10.8% in 2023
• Based on end use, CMO/CDMOs dominated the market, capturing a substantial revenue share of 70.2% in 2023

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Equipment
  • 1.2.2. Unit Operation
  • 1.2.3. Type
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Equipment Outlook
  • 2.2.2. Unit Operation
  • 2.2.3. Type
  • 2.2.4. End Use
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Continuous Manufacturing for Small Molecule APIs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rapid growth in the global pharmaceutical industry
    • 3.2.1.2. Growing role of flow chemistry in API manufacturing
    • 3.2.1.3. Growing adoption and improved efficiency & productivity
    • 3.2.1.4. Emergence as a green, sustainable and profitable process technology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High R&D investment and capital cost
    • 3.2.2.2. Regulatory compliance and process validation
• 3.3. Continuous Manufacturing for Small Molecule APIs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Continuous Manufacturing for Small Molecule APIs Market: Equipment Estimates & Trend Analysis

• 4.1. Global Continuous Manufacturing for Small Molecule APIs Market: Equipment Dashboard
• 4.2. Global Continuous Manufacturing for Small Molecule APIs Market: Equipment Movement Analysis
• 4.3. Global Continuous Manufacturing for Small Molecule APIs Market by Equipment, Revenue
• 4.4. Reactors
  • 4.4.1. Reactors market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Crystallizers
  • 4.5.1. Crystallizers market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Filtration Systems
  • 4.6.1. Filtration Systems market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Mixers
  • 4.7.1. Mixers market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Heat Exchangers
  • 4.8.1. Heat Exchangers market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Others (Dryers, etc.)
  • 4.9.1. Others (Dryers, etc.) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Continuous Manufacturing for Small Molecule APIs Market: Unit Operation Estimates & Trend Analysis

• 5.1. Global Continuous Manufacturing for Small Molecule APIs Market: Unit Operation Dashboard
• 5.2. Global Continuous Manufacturing for Small Molecule APIs Market: Unit Operation Movement Analysis
• 5.3. Global Continuous Manufacturing for Small Molecule APIs Market Estimates and Forecasts, By Unit Operation, Revenue (USD Million)
• 5.4. Synthesis
  • 5.4.1. Synthesis market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Separation & Purification
  • 5.5.1. Separation & Purification market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Drying
  • 5.6.1. Drying market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Continuous Manufacturing for Small Molecule APIs Market: Type Estimates & Trend Analysis

• 6.1. Global Continuous Manufacturing for Small Molecule APIs Market: Type Dashboard
• 6.2. Global Continuous Manufacturing for Small Molecule APIs Market: Type Movement Analysis
• 6.3. Global Continuous Manufacturing for Small Molecule APIs Market Estimates and Forecasts, By Type, Revenue (USD Million)
• 6.4. Generic APIs
  • 6.4.1. Generic APIs market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Innovative APIs
  • 6.5.1. Innovative APIs market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Continuous Manufacturing for Small Molecule APIs Market: End Use Estimates & Trend Analysis

• 7.1. Global Continuous Manufacturing for Small Molecule APIs Market: End Use Dashboard
• 7.2. Global Continuous Manufacturing for Small Molecule APIs Market: End Use Movement Analysis
• 7.3. Global Continuous Manufacturing for Small Molecule APIs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 7.4. CMOs/CDMOs
  • 7.4.1. CMOs/CDMOs market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Pharmaceutical Companies
  • 7.5.1. Pharmaceutical Companies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Academic & Research Institutes
  • 7.6.1. Academic & Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Continuous Manufacturing for Small Molecule APIs Market: Regional Estimates & Trend Analysis by Equipment, Unit Operation, Type and End Use

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key company market share analysis, 2023
  • 9.2.3. Pfizer Inc
    • 9.2.3.1. Company overview
    • 9.2.3.2. Financial performance
    • 9.2.3.3. Equipment benchmarking
    • 9.2.3.4. Strategic initiatives
  • 9.2.4. GSK plc. (GlaxoSmithKline)
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Equipment benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. Vertex Pharmaceuticals Incorporated
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Equipment benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. Janssen (a subsidiary of Johnson & Johnson)
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Equipment benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. Abbvie Inc.
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Equipment benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Sterling Pharma Solutions
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Equipment benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Evonik Industries AG
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Equipment benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Cambrex Corporation
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Equipment benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Patheon
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Equipment benchmarking
    • 9.2.11.4. Strategic initiatives
  • 9.2.12. Hovione
    • 9.2.12.1. Company overview
    • 9.2.12.2. Financial performance
    • 9.2.12.3. Equipment benchmarking
    • 9.2.12.4. Strategic initiatives
  • 9.2.13. Lonza
    • 9.2.13.1. Company overview
    • 9.2.13.2. Financial performance
    • 9.2.13.3. Equipment benchmarking
    • 9.2.13.4. Strategic initiatives
  • 9.2.14. Phlow
    • 9.2.14.1. Company overview
    • 9.2.14.2. Financial performance
    • 9.2.14.3. Equipment benchmarking
    • 9.2.14.4. Strategic initiatives
  • 9.2.15. Asymchem
    • 9.2.15.1. Company overview
    • 9.2.15.2. Financial performance
    • 9.2.15.3. Equipment benchmarking
    • 9.2.15.4. Strategic initiatives
  • 9.2.16. GEA Group AG
    • 9.2.16.1. Company overview
    • 9.2.16.2. Financial performance
    • 9.2.16.3. Equipment benchmarking
    • 9.2.16.4. Strategic initiatives
  • 9.2.17. Thermo Fisher Scientific
    • 9.2.17.1. Company overview
    • 9.2.17.2. Financial performance
    • 9.2.17.3. Equipment benchmarking
    • 9.2.17.4. Strategic initiatives
  • 9.2.18. Corning Incorporated
    • 9.2.18.1. Company overview
    • 9.2.18.2. Financial performance
    • 9.2.18.3. Equipment benchmarking
    • 9.2.18.4. Strategic initiatives
  • 9.2.19. Coperion GmbH
    • 9.2.19.1. Company overview
    • 9.2.19.2. Financial performance
    • 9.2.19.3. Equipment benchmarking
    • 9.2.19.4. Strategic initiatives
  • 9.2.20. Continuus Pharmaceuticals
    • 9.2.20.1. Company overview
    • 9.2.20.2. Financial performance
    • 9.2.20.3. Equipment benchmarking
    • 9.2.20.4. Strategic initiatives
  • 9.2.21. Chemtrix
    • 9.2.21.1. Company overview
    • 9.2.21.2. Financial performance
    • 9.2.21.3. Equipment benchmarking
    • 9.2.21.4. Strategic initiatives
  • 9.2.22. Vapourtec Ltd
    • 9.2.22.1. Company overview
    • 9.2.22.2. Financial performance
    • 9.2.22.3. Equipment benchmarking
    • 9.2.22.4. Strategic initiatives
  • 9.2.23. Ehrfeld Mikrotechnik GmbH
    • 9.2.23.1. Company overview
    • 9.2.23.2. Financial performance
    • 9.2.23.3. Equipment benchmarking
    • 9.2.23.4. Strategic initiatives
  • 9.2.24. NiTech Solutions Ltd
    • 9.2.24.1. Company overview
    • 9.2.24.2. Financial performance
    • 9.2.24.3. Equipment benchmarking
    • 9.2.24.4. Strategic initiatives

관련자료